Your browser is no longer supported. Please, upgrade your browser.
INSM Insmed Incorporated daily Stock Chart
Insmed Incorporated
Index- P/E- EPS (ttm)-2.82 Insider Own1.20% Shs Outstand89.78M Perf Week-5.85%
Market Cap2.78B Forward P/E- EPS next Y-1.72 Insider Trans0.00% Shs Float83.78M Perf Month-2.79%
Income-246.50M PEG- EPS next Q-0.69 Inst Own97.20% Short Float16.27% Perf Quarter51.30%
Sales151.40M P/S18.34 EPS this Y28.70% Inst Trans-1.99% Short Ratio11.77 Perf Half Y7.87%
Book/sh2.30 P/B12.10 EPS next Y39.40% ROA-33.00% Target Price44.11 Perf Year19.59%
Cash/sh4.30 P/C6.47 EPS next 5Y- ROE-87.40% 52W Range12.09 - 34.94 Perf YTD16.58%
Dividend- P/FCF- EPS past 5Y-10.40% ROI-38.20% 52W High-20.32% Beta2.76
Dividend %- Quick Ratio6.50 Sales past 5Y- Gross Margin81.20% 52W Low130.27% ATR1.59
Employees435 Current Ratio6.90 Sales Q/Q68.50% Oper. Margin- RSI (14)51.31 Volatility4.87% 5.73%
OptionableYes Debt/Eq1.75 EPS Q/Q22.70% Profit Margin- Rel Volume0.32 Prev Close27.97
ShortableYes LT Debt/Eq1.74 EarningsApr 30 BMO Payout- Avg Volume1.16M Price27.84
Recom1.80 SMA20-1.03% SMA506.17% SMA20022.98% Volume371,210 Change-0.46%
Sep-03-19Initiated Goldman Buy $30
Apr-09-19Reiterated H.C. Wainwright Buy $43 → $52
Feb-15-19Upgrade JMP Securities Mkt Perform → Mkt Outperform $40
Jan-17-19Upgrade Goldman Neutral → Buy
Jan-02-19Initiated Canaccord Genuity Buy $20
Aug-06-18Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jul-23-18Initiated Goldman Neutral $32
Apr-23-18Upgrade Credit Suisse Neutral → Outperform
Mar-21-18Initiated Morgan Stanley Overweight $39
Jan-18-18Initiated Credit Suisse Neutral $31
Sep-05-17Reiterated Evercore ISI Outperform $28 → $40
Aug-17-17Initiated Evercore ISI Outperform $28
Jul-11-17Initiated Robert W. Baird Outperform $23
Mar-15-16Initiated Stifel Buy $23
Nov-09-15Downgrade UBS Buy → Neutral $35 → $18
Oct-06-15Reiterated H.C. Wainwright Buy $30 → $35
Jun-09-15Initiated Citigroup Neutral $27
Mar-26-14Reiterated HC Wainwright Buy $25 → $30
Jan-06-14Reiterated UBS Buy $17.50 → $31
Nov-11-13Initiated HC Wainwright Buy $25
Jul-07-20 08:00AM  
Jul-06-20 08:00AM  
Jun-29-20 08:30AM  
Jun-28-20 05:26PM  
Jun-24-20 04:01PM  
Jun-23-20 04:03PM  
Jun-19-20 11:58AM  
Jun-08-20 08:00AM  
Jun-05-20 08:00AM  
May-26-20 08:00AM  
May-25-20 01:15PM  
May-20-20 09:29AM  
May-19-20 09:47AM  
May-07-20 10:46AM  
May-05-20 08:00AM  
May-04-20 04:01PM  
May-01-20 03:01PM  
Apr-30-20 09:05AM  
Apr-29-20 09:47AM  
Apr-23-20 12:32PM  
Apr-20-20 08:00AM  
Apr-13-20 09:12AM  
Apr-07-20 03:33PM  
Apr-03-20 08:00AM  
Apr-02-20 08:00AM  
Mar-17-20 08:48AM  
Mar-16-20 04:01PM  
Mar-05-20 08:00AM  
Mar-04-20 08:00AM  
Mar-02-20 04:56PM  
Feb-27-20 08:13AM  
Feb-26-20 08:00AM  
Feb-25-20 08:55AM  
Feb-20-20 08:15AM  
Feb-19-20 08:00AM  
Feb-10-20 08:00AM  
Feb-05-20 07:43AM  
Feb-04-20 10:20AM  
Feb-03-20 04:14PM  
Jan-30-20 08:00AM  
Jan-09-20 08:00AM  
Jan-03-20 04:05PM  
Jan-01-20 02:24PM  
Dec-07-19 05:50PM  
Dec-03-19 04:05PM  
Nov-18-19 03:29AM  
Nov-14-19 08:00AM  
Nov-05-19 08:00AM  
Nov-04-19 04:05PM  
Nov-02-19 08:32AM  
Oct-31-19 09:26AM  
Oct-30-19 08:55AM  
Oct-27-19 04:14PM  
Oct-23-19 08:00AM  
Oct-21-19 10:54AM  
Oct-17-19 03:30PM  
Oct-07-19 04:05PM  
Sep-18-19 09:11AM  
Sep-05-19 04:05PM  
Sep-03-19 08:00AM  
Aug-13-19 11:58AM  
Aug-02-19 04:05PM  
Aug-01-19 02:46PM  
Jul-25-19 08:00AM  
Jul-02-19 04:05PM  
Jun-26-19 04:41PM  
Jun-25-19 06:15PM  
Jun-11-19 04:38PM  
Jun-06-19 08:00AM  
Jun-04-19 04:05PM  
Jun-02-19 01:45AM  
May-24-19 11:27AM  
May-22-19 10:53AM  
May-21-19 08:56PM  
May-20-19 04:05PM  
May-07-19 11:24PM  
May-02-19 01:55PM  
May-01-19 07:20AM  
Apr-30-19 08:00AM  
Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients in the United States. It also develops INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug for the treatment of rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLL JOHNChief Accounting OfficerNov 18Option Exercise12.5825,000314,50032,322Nov 20 04:10 PM
GOLL JOHNChief Accounting OfficerNov 18Sale20.0425,000501,0007,322Nov 20 04:10 PM